Development Pipeline
Using aiProtein® technology, we design gain-of-function (GOF) enzymes to overcome the challenges of mRNA therapy, developing “GOF-enhanced mRNA therapeutics.” This approach is expected to be applicable to a wide range of inherited diseases as a new therapeutic modality.
As of Feburary, 2026
| Project | Indication | Partner | Lead Discovery | PreClinical | Clinical | ||
|---|---|---|---|---|---|---|---|
| Ph1 | Ph2 | Ph3 | |||||
| RKD001/003 | Rare Disease |
|
|||||
| RKD002 | Rare Disease |
|
|||||
| RKD004 | Rare Disease | Undisclosed | |||||
